Long-term Safety and Efficacy Study of MND-2119 in Patients With Hypertriglyceridemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT04221217

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04221217
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04221217. Randomized; no masking; primary purpose treatment. Start 2020-02-14 (actual); primary completion 2021-07-14 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Long-term Safety and Efficacy Study of MND-2119 in Patients With Hypertriglyceridemia
Condition
Hypertriglyceridemia
Intervention (Drug)
Icosapent
Lead sponsor
Mochida Pharmaceutical Company, Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04221217
Content hash
f8d51aea8ea28a3576761638d2535662566eb54d5e076d9762f54ea161e8eeaf